Silymarin Ameliorates Tacrolimus-induced Inflammation in Human Umbilical Vein Endothelial Cells

TAC directly promotes an inflammatory phenotype in HUVECs. SM effectively counteracts this TAC-induced endothelial inflammation <i>in vitro</i>. These findings suggest that silymarin, potentially through its antioxidant and NF-κB inhibitory actions, could be explored as a therapeutic agent to mitigate the vascular inflammation and endothelial dysfunction associated with TAC treatment in transplant recipients, potentially reducing cardiovascular complications.